

GOV. MSG. NO. 1334

EXECUTIVE CHAMBERS

NEIL ABERCROMBIE GOVERNOR

July 12, 2011

The Honorable Shan Tsutsui, President and Members of the Senate Twenty-Sixth State Legislature State Capitol, Room 409 Honolulu, Hawaii 96813 The Honorable Calvin Say, Speaker and Members of the House Twenty-Sixth State Legislature State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Tsutsui, Speaker Say and Members of the Legislature:

This is to inform you that on July 12, 2011, the following bill was signed into law:

SB1274 SD2 HD3 CD1

RELATING TO HEALTH INSURANCE Act 230 (11)

Thecombri

NEIL ABERCROMBIE Governor, State of Hawaii

Approved by the Governor

JUL 1 2 2011

THE SENATE TWENTY-SIXTH LEGISLATURE, 2011 STATE OF HAWAII

A BILL FOR AN ACT

ACT 230 S.B. NO. ¹²⁷⁴ H.D. 3

C.D. 1

RELATING TO HEALTH INSURANCE.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. The legislature finds that the purpose of this
2	Act is to comply with the requirements of the Patient Protection
3	and Affordable Care Act of 2010, Public Law No. 111-148, and its
4	implementing regulations by updating Hawaii's Patients' Bill of
5	Rights and Responsibilities Act, chapter 432E, Hawaii Revised
6	Statutes, to conform to the requirements of the federal law.
7	SECTION 2. Chapter 432E, Hawaii Revised Statutes, is
8	amended by adding a new part to be appropriately designated and
9	to read as follows:
10	"PART . EXTERNAL REVIEW OF HEALTH
11	INSURANCE DETERMINATIONS
11 12	INSURANCE DETERMINATIONS §432E-A Applicability and scope. (a) Except as provided
12	§432E-A Applicability and scope. (a) Except as provided
12 13	§432E-A Applicability and scope . (a) Except as provided in subsection (b), this part shall apply to all health carriers.
12 13 14	<pre>\$432E-A Applicability and scope. (a) Except as provided in subsection (b), this part shall apply to all health carriers. (b) This part shall not apply to a policy or certificate</pre>
12 13 14 15	<pre>\$432E-A Applicability and scope. (a) Except as provided in subsection (b), this part shall apply to all health carriers. (b) This part shall not apply to a policy or certificate that provides coverage only for a specified disease, specified</pre>
12 13 14 15 16	<pre>\$432E-A Applicability and scope. (a) Except as provided in subsection (b), this part shall apply to all health carriers. (b) This part shall not apply to a policy or certificate that provides coverage only for a specified disease, specified accident or accident-only coverage, credit, dental, disability</pre>

S.B. NO. ¹²⁷⁴ ^{S.D. 2} ^{H.D. 3}

1 supplemental policy of insurance, coverage under a plan through 2 medicare, medicaid, or the federal employees health benefits 3 program, any federal medical and dental care coverage issued 4 under chapter 55 of Title 10 United States Code and any coverage issued as supplemental to that coverage; any coverage issued as 5 6 supplemental to liability insurance, workers' compensation, or 7 similar insurance; automobile medical-payment insurance; any 8 insurance under which benefits are payable with or without 9 regard to fault, whether written on a group blanket or 10 individual basis; or the employer union health benefits trust 11 fund so long as it is self-funded.

12 §432E-B Notice of right to external review. Notice of the 13 right to external review issued pursuant to this part shall set 14 forth the options available to the enrollee under this part. 15 The commissioner may specify the form and content of notice of 16 external review.

17 §432E-C Request for external review. (a) All requests 18 for external review of a health carrier's adverse action shall 19 be made in writing to the commissioner and shall include: 20 (1) A copy of the final internal determination of the 21 health carrier, unless exempted pursuant to subsection 22 (b);



S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	(2) A signed authorization by or on behalf of the enrollee
2	for release of the enrollee's medical records relevant
3	to the external review;
4	(3) A disclosure for conflict of interests evaluation, as
5	provided in section 432E-M; and
6	(4) A filing fee of \$15, which shall be deposited into the
7	compliance resolution fund established pursuant to
8	section 26-9(0); provided that the filing fee shall be
9	refunded if the adverse determination or final
10	internal adverse determination is reversed through
11	external review.
12	The commissioner shall waive the filing fee required by this
13	subsection if the commissioner determines that payment of the
14	fee would impose an undue financial hardship to the enrollee.
15	The annual aggregate limit on filing fees for any enrollee
16	within a single plan year shall not exceed \$60.
17	(b) The internal appeals process of a health carrier shall
18	be completed before an external review request shall be
19	submitted to the commissioner except in the following
20	circumstances:
21	(1) The health carrier has waived the requirement of
22	exhaustion of the internal appeals process;
	2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

C.D. 1

1	(2)	The enrollee has applied for an expedited external
2		review at the same time that the enrollee applied for
3		an expedited internal appeal; provided that the
4		enrollee is eligible for an expedited external review;
5		or

6 (3) The health carrier has substantially failed to comply
7 with its internal appeals process.

8 §432E-D Standard external review. (a) An enrollee or the 9 enrollee's appointed representative may file a request for an 10 external review with the commissioner within one hundred thirty 11 days of receipt of notice of an adverse action. Within three 12 business days after the receipt of a request for external review 13 pursuant to this section, the commissioner shall send a copy of 14 the request to the health carrier.

(b) Within five business days following the date of receipt of the copy of the external review request from the commissioner pursuant to subsection (a), the health carrier shall determine whether:

19 (1) The individual is or was an enrollee in the health
20 benefit plan at the time the health care service was
21 requested or, in the case of a retrospective review,

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

was an enrollee in the health benefit plan at the time the health care service was provided; (2)The health care service that is the subject of the adverse determination or the final adverse determination would be a covered service under the enrollee's health benefit plan but for a determination by the health carrier that the health care service does not meet the health carrier's requirements for medical necessity, appropriateness, health care setting, level of care, or effectiveness; The enrollee has exhausted the health carrier's (3)internal appeals process or the enrollee is not required to exhaust the health carrier's internal appeals process pursuant to section 432E-C(b); and (4)The enrollee has provided all the information and forms required to process an external review, including a completed release form and disclosure form as required by section 432E-C(a).

(c) Within three business days after a determination of an
enrollee's eligibility for external review pursuant to
subsection (b), the health carrier shall notify the
commissioner, the enrollee, and the enrollee's appointed

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

C.D. 1

1 representative in writing as to whether the request is complete 2 and whether the enrollee is eligible for external review. 3 If the request for external review submitted pursuant to 4 this section is not complete, the health carrier shall inform the commissioner, the enrollee, and the enrollee's appointed 5 6 representative in writing that the request is incomplete and 7 shall specify the information or materials required to complete 8 the request. If the enrollee is not eligible for external review 9 pursuant to subsection (b), the health carrier shall inform the 10 commissioner, the enrollee, and the enrollee's appointed 11 representative in writing that the enrollee is not eligible for 12 external review and the reasons for ineligibility. 13 Notice of ineligibility for external review pursuant to 14 this section shall include a statement informing the enrollee 15 and the enrollee's appointed representative that a health 16

17 carrier's initial determination that the external review request 18 is ineligible for review may be appealed to the commissioner by 19 submission of a request to the commissioner.

20 (d) Upon receipt of a request for appeal pursuant to
21 subsection (c), the commissioner shall review the request for
22 external review submitted by the enrollee pursuant to subsection



S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3 C.D. 1

1 (a), determine whether an enrollee is eligible for external 2 review and, if eligible, shall refer the enrollee to external 3 review. The commissioner's determination of eligibility for 4 external review shall be made in accordance with the terms of 5 the enrollee's health benefit plan and all applicable provisions 6 of this part. If an enrollee is not eligible for external 7 review, the commissioner shall notify the enrollee, the 8 enrollee's appointed representative, and the health carrier within three business days of the reason for ineligibility. 9 10 (e) When the commissioner receives notice pursuant to subsection (c) or makes a determination pursuant to subsection 11 (d) that an enrollee is eligible for external review, within 12 three business days after receipt of the notice or determination 13 of eligibility, the commissioner shall: 14

Randomly assign an independent review organization 15 (1) from the list of approved independent review 16 organizations qualified to conduct the external 17 review, based on the nature of the health care service 18 that is the subject of the adverse action and other 19 factors determined by the commissioner including 20 21 conflicts of interest pursuant to section 432E-M, 22 compiled and maintained by the commissioner to conduct

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1		the external review and notify the health carrier of
2		the name of the assigned independent review
3		organization; and
4	(2)	Notify the enrollee and the enrollee's appointed
5		representative, in writing, of the enrollee's
6		eligibility and acceptance for external review.
7	(f)	An enrollee or an enrollee's appointed representative
8	may submit	additional information in writing to the assigned
9	independen	t review organization for consideration in its
10	external r	eview. The independent review organization shall
11	consider i	nformation submitted within five business days
12	following	the date of the enrollee's receipt of the notice
13	provided p	ursuant to subsection (e). The independent review
14	organizati	on may accept and consider additional information
15	submitted	by an enrollee or an enrollee's appointed
16	representa	tive after five business days.
17	(g)	Within five business days after the date of receipt of
18	notice pur	suant to subsection (e), the health carrier or its
19	designated	utilization review organization shall provide to the

21 information it considered in issuing the adverse action that is
22 the subject of external review. Failure by the health carrier

assigned independent review organization all documents and

2011-2273 SB1274 CD1 SMA-3.doc

20

S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3

1 or its utilization review organization to provide the documents 2 and information within five business days shall not delay the conduct of the external review; provided that the assigned 3 4 independent review organization may terminate the external review and reverse the adverse action that is the subject of the 5 6 external review. The independent review organization shall notify the enrollee, the enrollee's appointed representative. 7 8 the health carrier, and the commissioner within three business 9 days of the termination of an external review and reversal of an 10 adverse action pursuant to this subsection.

11 (h) The assigned independent review organization shall, within one business day of receipt by the independent review 12 13 organization, forward all information received from the enrollee 14 pursuant to subsection (f) to the health carrier. Upon receipt 15 of information forwarded to it pursuant to this subsection, a 16 health carrier may reconsider the adverse action that is the subject of the external review; provided that reconsideration by 17 the health carrier shall not delay or terminate an external 18 19 review unless the health carrier reverses its adverse action and 20 provides coverage or payment for the health care service that is the subject of the adverse action. The health carrier shall 21 22 notify the enrollee, the enrollee's appointed representative,

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

10

the assigned independent review organization, and the 1 commissioner in writing of its decision to reverse its adverse 2 action within three business days of making its decision to 3 reverse the adverse action and provide coverage. The assigned 4 independent review organization shall terminate its external 5 review upon receipt of notice pursuant to this subsection from 6 the health carrier. 7 In addition to the documents and information provided 8 (i) pursuant to subsections (f) and (g), the assigned independent 9 review organization shall consider the following in reaching a 10 11 decision: The enrollee's medical records; 12 (1)The attending health care professional's 13 (2) 14 recommendation; Consulting reports from appropriate health care 15 (3) professionals and other documents submitted by the 16 health carrier, enrollee, enrollee's appointed 17 representatives, or enrollee's treating provider; 18 The application of medical necessity as defined in (4)19 section 432E-1; 20 The most appropriate practice guidelines, which shall 21 (5)include applicable evidence-based standards and may 22

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3

1 include any practice guidelines developed by the 2 federal government or national or professional medical societies, boards, and associations; 3 4 (6)Any applicable clinical review criteria developed and 5 used by the health carrier or its designated utilization review organization; and 6 7 The opinion of the independent review organization's (7) 8 clinical reviewer or reviewers pertaining to the information enumerated in paragraphs (1) through (5) 9 to the extent the information or documents are 10 available and the clinical reviewer or reviewers 11 12 consider appropriate. In reaching a decision, the assigned independent review 13

13 In reaching a decision, the assigned independent review 14 organization shall not be bound by any decisions or conclusions 15 reached during the health carrier's utilization review or 16 internal appeals process; provided that the independent review 17 organization's decision shall not contradict the terms of the 18 enrollee's health benefit plan or this part.

(j) Within forty-five days after it receives a request for
an external review pursuant to subsection (e), the assigned
independent review organization shall notify the enrollee, the
enrollee's appointed representative, the health carrier, and the

1 commissioner of its decision to uphold or reverse the adverse 2 action that is the subject of the internal review. The 3 independent review organization shall include in the notice of its decision: 4 5 (1)A general description of the reason for the request for external review; 6 The date the independent review organization received (2)7 the assignment from the commissioner to conduct the 8 external review; 9 10 (3) The date the external review was conducted; The date the decision was issued; and 11 (4)The basis for the independent review organization's 12 (5) decision, including its reasoning, rationale, and the 13 14 supporting evidence or documentation, including 15 evidence-based standards, that the independent review 16 organization considered in reaching its decision. 17 Upon receipt of a notice of a decision reversing the 18 adverse action, the health carrier shall immediately approve the 19 coverage that was the subject of the adverse action. §432E-E Expedited external review. (a) Except as 20 provided in subsection (i), an enrollee or the enrollee's 21

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 appointed representative may request an expedited external 2 review with the commissioner if the enrollee receives: (1)An adverse determination that involves a medical 3 condition of the enrollee for which the timeframe for 4 5 completion of an expedited internal appeal would 6 seriously jeopardize the enrollee's life, health, or ability to gain maximum functioning or would subject 7 the enrollee to severe pain that cannot be adequately 8 managed without the care or treatment that is the 9 10 subject of the adverse determination; A final adverse determination if the enrollee has a 11 (2) medical condition where the timeframe for completion 12 of a standard external review would seriously 13 jeopardize the enrollee's ability to gain maximum 14 functioning, or would subject the enrollee to severe 15 pain that cannot be adequately managed without the 16 care or treatment that is the subject of the adverse 17 determination; or 18 A final adverse determination if the final adverse 19 (3) determination concerns an admission, availability of 20 care, continued stay, or health care service for which 21 22 the enrollee received emergency services; provided

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 that the enrollee has not been discharged from a 2 facility for health care services related to the 3 emergency services. 4 Upon receipt of a request for an expedited external (b) 5 review, the commissioner shall immediately send a copy of the 6 request to the health carrier. Immediately upon receipt of the 7 request, the health carrier shall determine whether the request meets the reviewability requirements set forth in subsection 8 9 The health carrier shall immediately notify the enrollee (a). or the enrollee's appointed representative of its determination 10 of the enrollee's eligibility for expedited external review. 11 12 Notice of ineligibility for expedited external review shall include a statement informing the enrollee and the enrollee's 13 appointed representative that a health carrier's initial 14 determination that an external review request that is ineligible 15 16 for review may be appealed to the commissioner by submission of 17 a request to the commissioner.

(c) Upon receipt of a request for appeal pursuant to
subsection (b), the commissioner shall review the request for
expedited external review submitted pursuant to subsection (a)
and, if eligible, shall refer the enrollee for external review.
The commissioner's determination of eligibility for expedited

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

external review shall be made in accordance with the terms of
 the enrollee's health benefit plan and all applicable provisions
 of this part. If an enrollee is not eligible for expedited
 external review, the commissioner shall immediately notify the
 enrollee, the enrollee's appointed representative, and the
 health carrier of the reasons for ineligibility.

7 (d) If the commissioner determines that an enrollee is 8 eligible for expedited external review even though the enrollee 9 has not exhausted the health carrier's internal review process, 10 the health carrier shall not be required to proceed with its 11 internal review process. The health carrier may elect to proceed with its internal review process even though the request 12 is determined by the commissioner to be eligible for expedited 13 external review; provided that the internal review process shall 14 not delay or terminate an expedited external review unless the 15 health carrier decides to reverse its adverse determination and 16 provide coverage or payment for the health care service that is 17 the subject of the adverse determination. Immediately after 18 making a decision to reverse its adverse determination, the 19 health carrier shall notify the enrollee, the enrollee's 20 21 authorized representative, the independent review organization assigned pursuant to subsection (c), and the commissioner in the 22

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

16

writing of its decision. The assigned independent review
 organization shall terminate the expedited external review upon
 receipt of notice from the health carrier pursuant to this
 subsection.

5 (e) Upon receipt of the notice pursuant to subsection (a) or a determination of the commissioner pursuant to subsection 6 7 (c) that the enrollee meets the eligibility requirements for expedited external review, the commissioner shall immediately 8 9 randomly assign an independent review organization to conduct 10 the expedited external review from the list of approved 11 independent review organizations qualified to conduct the 12 external review, based on the nature of the health care service 13 that is the subject of the adverse action and other factors 14 determined by the commissioner including conflicts of interest pursuant to section 432E-M, compiled and maintained by the 15 16 commissioner to conduct the external review and immediately notify the health carrier of the name of the assigned 17 18 independent review organization.

(f) Upon receipt of the notice from the commissioner of
the name of the independent review organization assigned to
conduct the expedited external review, the health carrier or its
designee utilization review organization shall provide or

1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.

17

1	transmit	all documents and information it considered in making
2	the adver	rse action that is the subject of the expedited external
3	review to	the assigned independent review organization
4	electroni	ically or by telephone, facsimile, or any other
5	available	e expeditious method.
6	(g)	In addition to the documents and information provided
7	or transm	nitted pursuant to subsection (f), the assigned
8	independe	ent review organization shall consider the following in
9	reaching	a decision:
10	(1)	The enrollee's pertinent medical records;
11	(2)	The attending health care professional's
12		recommendation;
13	(3)	Consulting reports from appropriate health care
14		professionals and other documents submitted by the
15		health carrier, enrollee, the enrollee's appointed
16		representative, or the enrollee's treating provider;
17	(4)	The application of medical necessity criteria as
18		defined in section 432E-1;
19	(5)	The most appropriate practice guidelines, which shall
20		include evidence-based standards, and may include any
21		other practice guidelines developed by the federal

S.B. NO. ¹²⁷⁴ ^{S.D. 2} H.D. 3 C.D. 1

18

1		government, national or professional medical
2		societies, boards, and associations;
3	(6)	Any applicable clinical review criteria developed and
4		used by the health carrier or its designee utilization
5		review organization in making adverse determinations;
6		and
7	(7)	The opinion of the independent review organization's
8		clinical reviewer or reviewers pertaining to the
9		information enumerated in paragraphs (1) through (5)
10	• •	to the extent the information and documents are
11		available and the clinical reviewer or reviewers
12		consider appropriate.
13	In re	eaching a decision, the assigned independent review
14	organizat	ion shall not be bound by any decisions or conclusions
15	reached di	uring the health carrier's utilization review or
16	internal a	appeals process; provided that the independent review
17	organizat:	ion's decision shall not contradict the terms of the
18	enrollee':	s health benefit plan or this part.

(h) As expeditiously as the enrollee's medical condition
or circumstances requires, but in no event more than seventy-two
hours after the date of receipt of the request for an expedited
external review that meets the reviewability requirements set

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	forth in subsection (a), the assigned independent review
2	organization shall:
3	(1) Make a decision to uphold or reverse the adverse
4	action; and
5	(2) Notify the enrollee, the enrollee's appointed
6	representative, the health carrier, and the
7	commissioner of the decision.
8	If the notice provided pursuant to this subsection was not
9	in writing, within forty-eight hours after the date of providing
10	that notice, the assigned independent review organization shall
11	provide written confirmation of the decision to the enrollee,
12	the enrollee's appointed representative, the health carrier, and
13	the commissioner that includes the information provided in
14	section 432E-G.
15	Upon receipt of the notice of a decision reversing the
16	adverse action, the health carrier shall immediately approve the
17	coverage that was the subject of the adverse action.
18	(i) An expedited external review shall not be provided for
19	retrospective adverse or final adverse determinations.
20	§432E-F External review of experimental or investigational
21	treatment adverse determinations. (a) An enrollee or an
22	enrollee's appointed representative may file a request for an
	2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

external review with the commissioner within one hundred thirty
 days of receipt of notice of an adverse action that involves a
 denial of coverage based on a determination that the health care
 service or treatment recommended or requested is experimental or
 investigational.

6 (b) An enrollee or the enrollee's appointed representative 7 may make an oral request for an expedited external review of the 8 adverse action if the enrollee's treating physician certifies, 9. in writing, that the health care service or treatment that is the subject of the request would be significantly less effective 10 if not promptly initiated. A written request for an expedited 11 external review pursuant to this subsection shall include, and 12 oral request shall be promptly followed by, a certification 13 14 signed by the enrollee's treating physician and the authorization for release and disclosures required by section 15 432E-C. Upon receipt of all items required by this subsection, 16 the commissioner shall immediately notify the health carrier. 17 (c) Upon notice of the request for expedited external 18 review, the health carrier shall immediately determine whether 19 the request meets the requirements of subsection (b). 20 The

21 health carrier shall immediately notify the commissioner, the

S.B. NO, ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

enrollee, and the enrollee's appointed representative of its
 eligibility determination.

Notice of eligibility for expedited external review pursuant to this subsection shall include a statement informing the enrollee and, if applicable, the enrollee's appointed representative that a health carrier's initial determination that the external review request is ineligible for review may be appealed to the commissioner.

9 Upon receipt of a request for appeal pursuant to (d) 10 subsection (c), the commissioner shall review the request for 11 external review submitted by the enrollee pursuant to subsection 12 (a), determine whether an enrollee is eligible for external review and, if eligible, shall refer the enrollee to external 13 The commissioner's determination of eligibility for 14 review. external review shall be made in accordance with the terms of 15 16 the enrollee's health benefit plan and all applicable provisions 17 of this part. If an enrollee is not eligible for external review, the commissioner shall notify the enrollee, the 18 19 enrollee's appointed representative, and the health carrier of the reason for ineligibility within three business days. 20

(e) Upon receipt of the notice pursuant to subsection (a)
or a determination of the commissioner pursuant to subsection

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 (d) that the enrollee meets the eligibility requirements for 2 expedited external review, the commissioner shall immediately randomly assign an independent review organization to conduct 3 4 the expedited external review from the list of approved 5 independent review organizations qualified to conduct the external review, based on the nature of the health care service 6 7 that is the subject of the adverse action and other factors 8 determined by the commissioner including conflicts of interest 9 pursuant to section 432E-M, compiled and maintained by the commissioner to conduct the external review and immediately 10 notify the health carrier of the name of the assigned 11 12 independent review organization.

Upon receipt of the notice from the commissioner of 13 (f) the name of the independent review organization assigned to 14 conduct the expedited external review, the health carrier or its 15 16 designee utilization review organization shall provide or transmit all documents and information it considered in making 17 the adverse action that is the subject of the expedited external 18 review to the assigned independent review organization 19 electronically or by telephone, facsimile, or any other 20 available expeditious method. 21

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

1 (g) Except for a request for an expedited external review 2 made pursuant to subsection (b), within three business days after the date of receipt of the request, the commissioner shall 3 notify the health carrier that the enrollee has requested an 4 5 expedited external review pursuant to this section. Within five business days following the date of receipt of notice, the 6 health carrier shall determine whether: 7 (1)The individual is or was an enrollee in the health 8 9 benefit plan at the time the health care service or treatment was recommended or requested or, in the case 10 11 of a retrospective review, was an enrollee in the 12 health benefit plan at the time the health care 13 service or treatment was provided; 14 (2)The recommended or requested health care service or treatment that is the subject of the adverse action: 15 Would be a covered benefit under the enrollee's 16 (A) 17 health benefit plan but for the health carrier's determination that the service or treatment is 18 experimental or investigational for the 19 20 enrollee's particular medical condition; and 21 (B) Is not explicitly listed as an excluded benefit 22 under the enrollee's health benefit plan;

The enrollee's treating physician has certified in 1 (3) writing that: 2 (A) Standard health care services or treatments have 3 not been effective in improving the condition of 4 the enrollee; 5 (B) Standard health care services or treatments are 6 not medically appropriate for the enrollee; or 7 (C) There is no available standard health care 8 9 service or treatment covered by the health carrier that is more beneficial than the health 10 care service or treatment that is the subject of 11 12 the adverse action; 13 (4) The enrollee's treating physician: Has recommended a health care service or 14 (A) 15 treatment that the physician certifies, in 16 writing, is likely to be more beneficial to the 17 enrollee, in the physician's opinion, than any available standard health care services or 18 19 treatments; or Who is a licensed, board certified or board 20 (B) 21 eligible physician qualified to practice in the 22 area of medicine appropriate to treat the

S.B. NO. ¹²⁷⁴ S.D. 2

24

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

enrollee's condition, has certified in writing 1 that scientifically valid studies using accepted 2 protocols demonstrate that the health care 3 service or treatment that is the subject of the 4 adverse action is likely to be more beneficial to 5 the enrollee than any available standard health 6 care services or treatments; 7 The enrollee has exhausted the health carrier's 8 (5)internal appeals process or the enrollee is not 9 required to exhaust the health carrier's internal 10 appeals process pursuant to section 432E-C(b); and 11 The enrollee has provided all the information and 12 (6) forms required by the commissioner that are necessary 13 14 to process an external review, including the release 15 form and disclosure of conflict of interest information as provided under section 432E-5. 16 17 (h) Within three business days after determining the enrollee's eligibility for external review pursuant to 18 subsection (q), the health carrier shall notify the 19 20 commissioner, the enrollee, and the enrollee's appointed 21 representative in writing as to whether the request is complete and eligible for external review. 22 .

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C D. 1

If the request is not complete, the health carrier shall
 inform the commissioner, the enrollee, and the enrollee's
 appointed representative in writing of the information or
 materials needed to complete the request.

5 If the enrollee is not eligible for external review 6 pursuant to subsection (g), the health carrier shall inform the 7 commissioner, the enrollee, and the enrollee's appointed 8 representative in writing of the ineligibility and the reasons 9 for ineligibility.

10 Notice of ineligibility pursuant to this subsection shall 11 include a statement informing the enrollee and the enrollee's 12 appointed representative that a health carrier's initial 13 determination that the external review request is ineligible for 14 review may be appealed to the commissioner by submitting a 15 request to the commissioner.

16 If a request for external review is determined eligible for 17 external review, the health carrier shall notify the 18 commissioner and the enrollee and, if applicable, the enrollee's 19 appointed representative.

20 (i) Upon receipt of a request for appeal pursuant to
21 subsection (h), the commissioner shall review the request for
22 external review submitted pursuant to subsection (a) and, if

S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3 C.D. 1

eligible, shall refer the enrollee for external review. 1 The 2 commissioner's determination of eligibility for expedited 3 external review shall be made in accordance with the terms of the enrollee's health benefit plan and all applicable provisions 4 5 of this part. If an enrollee is not eligible for external 6 review, the commissioner shall notify the enrollee, the enrollee's appointed representative, and the health carrier of 7 8 the reasons for ineligibility within three business days.

9 (j) When the commissioner receives notice pursuant to
10 subsection (h) or makes a determination pursuant to subsection
11 (i) that an enrollee is eligible for external review, within
12 three business days after receipt of the notice or determination
13 of eligibility, the commissioner shall:

Randomly assign an independent review organization 14 (1) from the list of approved independent review 15 16 organizations qualified to conduct the external review, based on the nature of the health care service ·17 that is the subject of the adverse action and other 18 factors determined by the commissioner including 19 conflicts of interest pursuant to section 432E-M, 20 21 compiled and maintained by the commissioner pursuant 22 to conduct the external review and notify the health

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

28

1	carrier of the name of the assigned independent review
2	organization; and
3	(2) Notify the enrollee and the enrollee's appointed
4	representative, in writing, of the enrollee's
5	eligibility and acceptance for external review.
6	(k) An enrollee or an enrollee's appointed representative
7	may submit additional information in writing to the assigned
8	independent review organization for consideration in its
9	external review. The independent review organization shall
10	consider information submitted within five business days
11	following the date of the enrollee's receipt of the notice
12	provided pursuant to subsection (j). The independent review
13	organization may accept and consider additional information
14	submitted by an enrollee after five business days.
15	(1) Within five business days after the date of receipt of
16	notice pursuant to subsection (j), the health carrier or its
17	designated utilization review organization shall provide to the
18	assigned independent review organization all documents and
19	information it considered in issuing the adverse action that is
20	the subject of external review. Failure by the health carrier
21	or its utilization review organization to provide the documents
22	and information within five business days shall not delay the

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3

conduct of the external review; provided that the assigned 1 2 independent review organization may terminate the external 3 review and reverse the adverse action that is the subject of the external review. The independent review organization shall 4 5 notify the enrollee, the enrollee's appointed representative, 6 the health carrier, and the commissioner within three business 7 days of the termination of an external review and reversal of an 8 adverse action pursuant to this subsection.

9 (m) Within three business days after the receipt of the 10 notice of assignment to conduct the external review pursuant to 11 subsection (j), the assigned independent review organization 12 shall:

13 Select one or more clinical reviewers who each shall (1) be a physician or other health care professional who 14 meets the minimum qualifications described in section 15 432E-I and, through clinical experience in the past 16 three years, is an expert in the treatment of the 17 enrollee's condition and knowledgeable about the 18 recommended or requested health care service or 19 . treatment to conduct the external review; provided 20 21 that neither the enrollee, the enrollee's appointed 22 representative, nor the health carrier shall choose or

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

control the choice of the physicians or other health 1 2 care professionals to be selected to conduct the external review; and 3 4 Based on the written opinion of the clinical reviewer, (2)or opinions if more than one clinical reviewer has 5 6 been selected, to the assigned independent review organization on whether the recommended or requested 7 8 health care service or treatment should be covered, make a determination to uphold or reverse the adverse 9 10 action. In reaching an opinion, the clinical reviewers are not 11

In reaching an opinion, the clinical reviewers are not bound by any decisions or conclusions reached during the health carrier's utilization review process or internal appeals process.

Each clinical reviewer selected pursuant to this subsection shall review all of the information and documents received pursuant to subsection (1) and any other information submitted in writing by the enrollee or the enrollee's authorized representative pursuant to this subsection.

20 (n) The assigned independent review organization, within
21 one business day of receipt by the independent review
22 organization, shall forward all information received from the

S.B. NO. ¹²⁷⁴ S.D. 2 HD 3

C.D. 1

enrollee pursuant to subsection (k) to the health carrier. 1 Upon 2 receipt of information forwarded to it pursuant to this 3 subsection, a health carrier may reconsider the adverse action 4 that is the subject of the external review; provided that 5 reconsideration by the health carrier shall not delay or 6 terminate an external review unless the health carrier reverses 7 its adverse action and provides coverage or payment for the 8 health care service that is the subject of the adverse action. 9 The health carrier shall notify the enrollee, the enrollee's 10 appointed representative, the assigned independent review 11 organization, and the commissioner in writing of its decision to 12 reverse its adverse action and within three business days of 13 making its decision to reverse the adverse action and provide 14 The assigned independent review organization shall coverage. terminate its external review upon receipt of notice pursuant to 15 this subsection from the health carrier. 16

(o) Except as provided in subsection (p), within twenty
days after being selected to conduct the external review, a
clinical reviewer shall provide an opinion to the assigned
independent review organization pursuant to subsection (q)
regarding whether the recommended or requested health care

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

12

service or treatment subject to an appeal pursuant to this 1 2 section shall be covered. The clinical reviewers' opinion shall be in writing and 3 shall include: 4 A description of the enrollee's medical condition; 5 (1)(2)A description of the indicators relevant to 6 7 determining whether there is sufficient evidence to demonstrate that the recommended or requested health 8 9 care service or treatment is more likely than not to 10 be more beneficial to the enrollee than any available 11 standard health care services or treatments and whether the adverse risks of the recommended or 12 requested health care service or treatment would not 13 be substantially increased over those of available 14 standard health care services or treatments; 15 A description and analysis of any medical or 16 (3')scientific evidence, as that term is defined in 17 section 432E-1.4, considered in reaching the opinion; 18 A description and analysis of any medical necessity 19 (4)criteria defined in section 432E-1; and 20 Information on whether the reviewer's rationale for 21 (5) the opinion is based on approval of the health care 22

S.B. NO. ¹²⁷⁴ ^{S.D. 2} ^{H.D. 3}

1 service or treatment by the federal Food and Drug 2 Administration for the condition or medical or scientific evidence or evidence-based standards that 3 demonstrate that the expected benefits of the 4 5 recommended or requested health care service or 6 treatment is likely to be more beneficial to the 7 enrollee than any available standard health care services or treatments and the adverse risks of the 8 9 recommended or requested health care service or 10 treatment would not be substantially increased over 11 those of available standard health care services or 12 treatments.

(p) Notwithstanding the requirements of subsection (o), in an expedited external review, the clinical reviewer shall provide an opinion orally or in writing to the assigned independent review organization as expeditiously as the enrollee's medical condition or circumstances require, but in no event more than five calendar days after being selected in accordance with subsection (m).

20 If the opinion provided pursuant to this subsection was not 21 in writing, within forty-eight hours following the date the 22 opinion was provided, the clinical reviewer shall provide

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 G.D. 1²

14

1 written confirmation of the opinion to the assigned independent review organization and include the information required under 2 3 subsection (o). 4 (q) In addition to the documents and information provided pursuant to subsection (b) or (1), a clinical reviewer may 5 consider the following in reaching an opinion pursuant to 6 7 subsection (o): The enrollee's pertinent medical records; 8 (1)The attending physician's or health care 9 (2) professional's recommendation; 10 Consulting reports from appropriate health care 11 (3) professionals and other documents submitted by the 12 health carrier, enrollee, the enrollee's appointed 13 representative, or the enrollee's treating physician 14

16 (4) Whether:

15

17 (A) The recommended health care service or treatment
18 has been approved by the federal Food and Drug
19 Administration, if applicable, for the condition;
20 or

or health care professional; and

(B) Medical or scientific evidence or evidence-based
standards demonstrate that the expected benefits

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 of the recommended or requested health care 2 service or treatment is more likely than not to 3 be beneficial to the enrollee than any available standard health care service or treatment and the 4 5 adverse risks of the recommended or requested health care service or treatment would not be 6 substantially increased over those of available 7 standard health care services or treatments; 8 9 provided that the independent review organization's decision 10 shall not contradict the terms of the enrollee's health benefit plan or the provisions of this chapter. 11 12 Except as provided in subsection (s), within twenty (\mathbf{r}) days after the date it receives the opinion of the clinical 13 14 reviewer pursuant to subsection (0), the assigned independent 15 review organization, in accordance with subsection (t), shall 16 determine whether the health care service at issue in an 17 external review pursuant to this section shall be a covered benefit and shall notify the enrollee, the enrollee's appointed 18 19 representative, the health carrier, and the commissioner of its 20 determination. The independent review organization shall include in the notice of its decision: 21
S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	(1)	A general description of the reason for the request
2		for external review;
3	(2)	The written opinion of each clinical reviewer,
4	• •	including the recommendation of each clinical reviewer
5	r.	as to whether the recommended or requested health care
6		service or treatment should be covered and the
7		rationale for the reviewer's recommendation;
8	(3)	The date the independent review organization was
9		assigned by the commissioner to conduct the external
10		reviewer;
11	(4)	The date the external review was conducted;
12	(5)	The date the decision was issued;
13	(6)	The principal reason or reasons for its decision; and
14	(7)	The rationale for its decision.
15	Upon	receipt of a notice of a decision reversing the
16	adverse ac	ction, the health carrier immediately shall approve
17	coverage c	of the recommended or requested health care service or
18	treatment	that was the subject of the adverse action.
19	(s)	For an expedited external review, within forty-eight
20	hours afte	er the date it receives the opinion of each clinical
21	reviewer,	the assigned independent review organization, in
22	accordance	with subsection (t), shall make a decision and
	INTERFORMENT AND STRUCTURE FOR A DESCRIPTION OF A DESCRIP	SB1274 CD1 SMA-3.doc

S.B. NO.

37

1 provide notice of the decision orally or in writing to the 2 enrollee; the enrollee's appointed representative, the health 3 carrier, and the commissioner.

4 If the notice provided was not in writing, within forty-5 eight hours after the date of providing that notice, the 6 assigned independent review organization shall provide written 7 confirmation of the decision to the enrollee, the enrollee's appointed representative, the health carrier, and the 8 9 commissioner.

10 (t) If a majority of the clinical reviewers recommends 11 that the recommended or requested health care service or treatment should be covered, the independent review organization 12 13 shall make a decision to reverse the health carrier's adverse determination or final adverse determination. 14

15 If a majority of the clinical reviewers recommends that the 16 recommended or requested health care service or treatment should 17 not be covered, the independent review organization shall make a decision to uphold the health carrier's adverse determination or 18 final adverse determination. 19

If the clinical reviewers are evenly split as to whether 20 21 the recommended or requested health care service or treatment 22 should be covered, the independent review organization shall

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 obtain the opinion of an additional clinical reviewer in order for the independent review organization to make a decision based 2 3 on the opinions of a majority of the clinical reviewers. The 4 additional clinical reviewer shall use the same information to reach an opinion as the clinical reviewers who have already 5 6 submitted their opinions. The selection of the additional 7 clinical reviewer shall not extend the time within which the assigned independent review organization is required to make a 8 9 decision based on the opinions of the clinical reviewers 10 selected.

11 §432E-G Binding nature of external review decision. (a)
12 An external review decision shall be binding on the health
13 carrier and the enrollee except to the extent that the health
14 carrier or the enrollee has other remedies available under
15 applicable federal or state law.

(b) An enrollee or the enrollee's appointed representative
shall not file a subsequent request for external review
involving the same adverse action for which the enrollee has
already received an external review decision pursuant to this
part.

21 §432E-H Approval of independent review organizations. (a)
22 An independent review organization shall be approved by the

(b)

organization shall:

1

2

3

4

5

1274 S.D. 2 S.B. NO. commissioner in order to be eligible to be assigned to conduct external reviews under this part. To be eligible for approval by the commissioner to conduct external reviews under this part an independent review

6 (1) Submit an application on a form required by the commissioner and include all documentation and 7 information necessary for the commissioner to 8 9 determine if the independent review organization satisfies the minimum qualifications established under 10 this part; and 11

12 (2) Except as otherwise provided in subsection (c), shall be accredited by a nationally-recognized private 13 accrediting entity that the commissioner has 14 determined has independent review organization 15 accreditation standards that are equivalent to or 16 exceed the minimum standards established by this 17 section and section 432E-I. 18

The commissioner may approve independent review 19 (C) organizations that are not accredited by a nationally-recognized 20 private accrediting entity if there are no acceptable 21

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

nationally-recognized private accrediting entities providing
 independent review organization accreditation.

3 (d) The commissioner may charge an application fee that
4 the independent review organizations shall submit to the
5 commissioner with an application for approval and re-approval.

6 (e) Approval pursuant to this section is effective for two 7 years, unless the commissioner determines before its expiration that the independent review organization does not meet the 8 9 minimum qualifications established under this part. If the commissioner determines that an independent review organization 10 has lost its accreditation or no longer satisfies the minimum 11 requirements of this part, the commissioner shall terminate the 12 13 approval of the independent review organization and remove the independent review organization from the list of independent 14 review organizations approved to conduct external reviews 15 maintained by the commissioner. 16

17 (f) The commissioner shall maintain and periodically18 update a list of approved independent review organizations.

19 §432E-I Minimum qualifications for independent review
20 organizations. (a) To be eligible for approval under this part
21 to conduct external reviews, an independent review organization
22 shall have and maintain written policies and procedures that

govern all aspects of both the standard external review process 1 and the expedited external review process set forth in this part 2 that include, at minimum: 3 4 (1) A quality assurance mechanism in place that ensures: (A). That external reviews are conducted within the 5 specified time frames of this part and required 6 notices are provided in a timely manner; 7 The selection of qualified and impartial clinical 8 (B) reviewers to conduct external reviews on behalf 9 of the independent review organization and 10 suitable matching of reviewers to specific cases; 11 provided that an independent review organization 12 shall employ or contract with an adequate number 13 of clinical reviewers to meet this objective; 14 (C) Confidentiality of medical and treatment records 15 and clinical review criteria; and 16 (D) That any person employed by or under contract 17 with the independent review organization complies 18 with the requirements of this part; 19 Toll-free telephone, facsimile, and email capabilities 20 (2) to receive information related to external reviews 21 twenty-four hours a day, seven days per week that are 22

S.B. NO. ¹²⁷⁴ S.D. 2

1 capable of accepting, recording, or providing appropriate instruction to incoming telephone callers 2 during other than normal business hours and 3 facilitating necessary communication under this part; 4 and 5 6 (3) An agreement to maintain and provide to the commissioner the information required by this part. 7 8 (b) Each clinical reviewer assigned by an independent review organization to conduct an external review shall be a 9 physician or other appropriate health care provider who: 10 Is an expert in the treatment of the medical condition 11 (1)12 that is the subject of the external review; Is knowledgeable about the recommended health care 13 (2) service and treatment through recent or current actual 14 clinical experience treating patients with the same or 15 similar medical condition at issue in the external 16 review; 17 Holds a non-restricted license in a state of the 18 (3) United States and, for physicians, a current 19 certification by a recognized American Medical 20 Specialty Board in the area or areas appropriate to 21 the subject of the external review; and 22

S.B. NO. 5.D. 2

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

(4) Has no history of disciplinary actions or sanctions,
 including loss of staff privileges or participation
 restrictions, imposed or pending by any hospital,
 governmental agency or unit, or regulatory body that
 raises a substantial question as to the clinical
 reviewer's physical, mental, or professional
 competence or moral character.

8 (c) An independent review organization shall not own or 9 control, be a subsidiary of, or in any way be owned or 10 controlled by, or exercise control over a health carrier, health 11 benefit plan, a national, state, or local trade association of 12 health benefit plans, or a national, state, or local trade 13 association of health care providers.

(d) To be eligible to conduct an external review of a
specified case, neither the independent review organization
selected to conduct the external review nor any clinical
reviewer assigned by the independent review organization to
conduct the external review shall have a material professional,
familial, or financial conflict of interest with any of the
following:

(1) The health carrier that is the subject of the external
 review;

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	(2)	The enrollee whose treatment is the subject of the
2		external review, the enrollee's appointed
3		representative, or the enrollee's immediate family;
4	(3)	Any officer, director, or management employee of the
5		health carrier that is the subject of the external
6		review;
7	(4)	The health care provider, the health care provider's
8		medical group, or independent practice association
9		recommending the health care service or treatment that
10		is the subject of the external review;
11	(5)	The facility at which the recommended health care
12		service or treatment would be provided;
13	(6)	The developer or manufacturer of the principal drug,
14		device, procedure, or other therapy recommended for
15		the enrollee whose treatment is the subject of the
16		external review; or
17	(7)	The health benefit plan that is the subject of the
18		external review, the plan administrator, or any
19		fiduciary or employee of the plan.
20	The	commissioner may determine that no material
21	professio	nal, familial, or financial conflict of interest exists
22	based on	the specific characteristics of a particular
	LINEARY CALL PRINTERS IN COMPANY AND SALES	SB1274 CD1 SMA-3.doc

S.B. NO.

1 relationship or connection that creates an apparent professional, familial, or financial conflict of interest. 2 An independent review organization that is accredited 3. (e) 4 by a nationally-recognized private accrediting entity that has 5 independent review accreditation standards that the commissioner has determined are equivalent to or exceed the minimum 6 7 qualifications of this section shall be presumed to be in 8 compliance with this section to be eligible for approval under 9 this part.

10 The commissioner shall review, initially upon approval of an accredited independent review organization and periodically 11 12 during the time that the independent review organization remains approved pursuant to this section, the accreditation standards 13 of the nationally-recognized private accrediting entity to 14 determine whether the entity's standards are, and continue to be 15 16 equivalent to, or exceed the minimum qualifications established under this section; provided that a review conducted by the 17 National Association of Insurance Commissioners shall satisfy 18 the requirements of this section. 19

20 Upon request of the commissioner, a nationally-recognized private accrediting entity shall make its current independent 21 review organization accreditation standards available to the 22

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 commissioner or the National Association of Insurance Commissioners in order for the commissioner to determine if the 2 3 entity's standards are equivalent to or exceed the minimum 4 qualifications established under this section. The commissioner 5 may exclude any private accrediting entity that is not reviewed 6 by the National Association of Insurance Commissioners. 7 An independent review organization shall establish and (f) 8 maintain written procedures to ensure that it is unbiased in addition to any other procedures required under this section. 9 §432E-J Hold harmless for independent review 10 organizations. No independent review organization or clinical 11 12 reviewer working on behalf of an independent review organization or an employee, agent, or contractor of an independent review 13 organization shall be liable in damages to any person for any 14 opinions rendered or acts or omissions performed within the 15 scope of the organization's or person's duties under the law 16 during or upon completion of an external review conducted 17 pursuant to this part, unless the opinion was rendered or the 18 act or omission was performed in bad faith or involved gross 19 20 negligence.

21 §432E-K External review reporting requirements. (a) An
22 independent review organization assigned pursuant to this part
2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 to conduct an external review shall maintain written records in 2 the aggregate by state and by health carrier on all requests for 3 external review for which it conducted an external review during 4 a calendar year and upon request shall submit a report to the 5 commissioner, as required under subsection (b).

6 (b) Each independent review organization required to 7 maintain written records on all requests for external review 8 pursuant to subsection (a) for which it was assigned to conduct 9 an external review shall submit to the commissioner, upon 10 request, a report in the format specified by the commissioner. 11 The report shall include in the aggregate by state, and for each 12 health carrier:

13 (1) The total number of requests for external review;
14 (2) The number of requests for external review resolved
15 and, of those resolved, the number resolved upholding
16 the adverse action and the number resolved reversing
17 the adverse action;

18 (3) The average length of time for resolution;
19 (4) The summary of the types of coverages or cases for
20 which an external review was sought, as provided in
21 the format required by the commissioner;

1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.

1	(5)	The number of external reviews that were terminated as
2		the result of a reconsideration by the health carrier
3		of its adverse action after the receipt of additional
4		information from the enrollee or the enrollee's
5		appointed representative; and
6	(6)	Any other information the commissioner may request or
7		require.
8	The i	ndependent review organization shall retain the
9	written re	cords required pursuant to this subsection for at
10	least thre	e years.
11	(c)	Each health carrier shall maintain written records in
12	the aggreg	ate, by state and for each type of health benefit plan
13	offered by	the health carrier on all requests for external
14	review tha	t the health carrier receives notice of from the
15	commission	er pursuant to this part.
16	Each	health carrier required to maintain written records on
17	all reques	ts for external review shall submit to the
18	commission	er, upon request, a report in the format specified by
19	the commis	sioner that includes in the aggregate, by state, and
20	by type of	health benefit plan:
21	(1)	The total number of requests for external review;

1	(2)	From the total number of requests for external review
2		reported, the number of requests determined eligible
3		for a full external review; and
4	(3)	Any other information the commissioner may request or
5		require.
6	The l	health carrier shall retain the written records
7	required p	oursuant to this subsection for at least three years.
8	§4321	E-L Funding of external review. The health carrier
9.	against wh	nich a request for a standard external review or an
10	expedited	external review is filed shall pay the cost of the
11	independer	nt review organization for conducting the external
12	review. 7	There shall be no recourse against the commissioner for
13	the cost o	of conducting the external review and the selection of
14	an indeper	ndent review organization shall not be subject to
15	chapter 10	O3D; provided that the commissioner may initially
16	approve up	o to three independent review organizations to serve
17	beginning	on the effective date of this part until the initial
18	procuremer	it process is completed; provided further that in any
19	year in wh	nich procurement subject to chapter 103D does not
20	produce at	least three independent review organizations eligible
21	for select	ion under section 432E-I, the commissioner may approve

S.D. 2 H.D. 3 C.D. 1

S.B. NO.

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ s.D. 2 H.D. 3 C.D. 1

up to three independent review organizations notwithstanding the
 requirements of chapter 103D.

§432E-M Disclosure requirements. (a) Each health carrier
shall include a description of the external review procedures in
or attached to the policy, certificate, membership booklet,
outline of coverage, or other evidence of coverage it provides
to enrollees.

8 (b) Disclosure shall be in a format prescribed by the 9 commissioner and shall include a statement informing the 10 enrollee of the right of the enrollee to file a request for an external review of an adverse action with the commissioner. 11 The statement may explain that external review is available when the 12 adverse action involves an issue of medical necessity, 13 appropriateness, health care setting, level of care, or 14 effectiveness. The statement shall include the telephone number 15

16 and address of the commissioner.

(c) In addition to the requirements of subsection (b), the statement shall inform the enrollee that, when filing a request for an external review, the enrollee or the enrollee's appointed representative shall be required to authorize the release of any medical records of the enrollee that may be required to be reviewed for the purpose of reaching a decision on the external

S.B. NO. ¹²⁷⁴ s.D. 2 H.D. 3 C.D. 1

review and shall be required to provide written disclosures to
 permit the commissioner to perform a conflict of interest
 evaluation for selection of an appropriate independent review
 organization.

Each health carrier shall have available on its 5 (d) 6 website and provide upon request to any enrollee, forms for the 7 purpose of requesting an external review, which shall include an authorization release form that complies with the federal Health 8 9 Insurance Portability and Accountability Act as well as a 10 disclosure form for conflict of interest evaluation purposes that shall include the name of the enrollee, any authorized 11 12 representative acting on behalf of the enrollee, the enrollee's 13 immediate family members, the health carrier that is the subject of the external review, the health benefit plan, the plan 14 15 administrator, plan fiduciaries and plan employees if the 16 enrollee is in a group health benefits plan, the health care 17 providers treating the enrollee for purposes of the condition 18 that is the subject of the external review and the providers' 19 medical groups, the health care provider and facility at which 20 the requested health care service or treatment would be 21 provided, and the developer or manufacturer of the principal

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

52

drug, device, procedure, or other therapy that is the subject of
 the external review request.

3 (e) Each health carrier doing business in Hawaii shall 4 file with the commissioner by the effective date of this part, information to permit the commissioner to perform a conflict of 5 6 interest evaluation for selection of an appropriate independent 7 review organization in the event of a request for external 8 review involving the health carrier. A filing pursuant to this section shall include the name of the health carrier, its 9 10 officers, directors, and management employees. The health carrier shall promptly amend its filing with the commissioner 11 when there is any change of officers, directors, or managing 12 13 employees.

14 (f) The commissioner may prescribe the form or format to 15 use for the release authorization required by subsection (d) and 16 the conflict of interest disclosures required by subsections (d) 17 and (e).

(g) No disclosure required for purposes of this part shall
include lawyer-client privileged communications protected
pursuant to the Hawaii Rules of Evidence Rule 503.

21 §432E-N Rules. The insurance commissioner shall adopt
22 rules pursuant to chapter 91 to effectuate the purpose of this

2011-2273 SB1274 CD1 SMA-3.doc

1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.

1	part including requirements for forms to request external review
2	and expedited external review, to request approval by
3	independent review organizations, and for disclosure of
4	conflicts of interest by enrollees and health carriers."
5	SECTION 3. Chapter 432E, Hawaii Revised Statutes, is
6	amended by designating sections 432E-1 through 432E-2 as part I,
7	entitled "General Provisions".
8 .	SECTION 4. Chapter 432E, Hawaii Revised Statutes, is
9	amended by designating sections 432E-3 through 432E-8 as part
10	II, entitled "General Policies".
11	SECTION 5. Chapter 432E, Hawaii Revised Statutes, is
12	amended by designating sections 432E-9 through 432E-13 as part
13	III, entitled "Reporting and Other Provisions".
14	SECTION 6. Section 432E-1, Hawaii Revised Statutes, is
15	amended to read as follows:
16	"§432E-1 Definitions. As used in this chapter, unless the
17	context otherwise requires:
18	"Adverse action" means an adverse determination or a final
19	adverse determination.
20	"Adverse determination" means a determination by a health
21	carrier or its designated utilization review organization that
22	an admission, availability of care, continued stay, or other
	2011-2273 SB1274 CD1 SMA-3.doc »

1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.

1	health care service that is a covered benefit has been reviewed		
2	and, based upon the information provided, does not meet the		
3	health carrier's requirements for medical necessity,		
4	appropriateness, health care setting, level of care, or		
5	effectiveness, and the requested service or payment for the		
6	service is therefore denied, reduced, or terminated.		
7	"Ambulatory review" means a utilization review of health		
8	care services performed or provided in an outpatient setting.		
9	"Appeal" means a request from an enrollee to change a		
10	previous decision made by the [managed care-plan.] health		
11	carrier.		
12	"Appointed representative" means a person who is expressly		
13	permitted by the enrollee or who has the power under Hawaii law		
14	to make health care decisions on behalf of the enrollee,		
15	including:		
16	(1) A person to whom an enrollee has given express written		
17	consent to represent the enrollee in an external		
18	<u>review;</u>		
19	(2) A person authorized by law to provide substituted		
20	consent for an enrollee;		

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	(3) A family member of the enrollee or the enrollee's
2	treating health care professional, only when the
3	enrollee is unable to provide consent;
4	[(1)] <u>(4)</u> A court-appointed legal guardian;
5	$\left[\frac{1}{2}\right]$ (5) A person who has a durable power of attorney for
6	health care; or
7	[-(3)] (6) A person who is designated in a written advance
8	directive [-];
9	provided that an appointed representative shall include an
10	"authorized representative" as used in the federal Patient
11	Protection and Affordable Care Act.
12	"Best evidence" means evidence based on:
13	(1) Randomized clinical trials;
14	(2) If randomized clinical trials are not available,
15	cohort studies or case-control studies;
16	(3) If the trials in paragraphs (1) and (2) are not
17	available, case-series; or
18	(4) If the sources of information in paragraphs (1), (2),
19	and (3) are not available, expert opinion.
20	"Case management" means a coordinated set of activities
21	conducted for individual patient management of serious,
22	complicated, protracted, or other health conditions.

1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.

56

1	"Case-control study" means a prospective evaluation of two
2	groups of patients with different outcomes to determine which
3	specific interventions the patients received.
4	"Case-series" means an evaluation of patients with a
5	particular outcome, without the use of a control group.
6	"Certification" means a determination by a health carrier
7	or its designated utilization review organization that an
8	admission, availability of care, continued stay, or other health
9	care service has been reviewed and, based on the information
10	provided, satisfies the health carrier's requirements for
11	medical necessity, appropriateness, health care setting, level
12	of care, and effectiveness.
13	"Clinical review criteria" means the written screening
14	procedures, decision abstracts, clinical protocols, and practice
15	guidelines used by a health carrier to determine the necessity
16	and appropriateness of health care services.
17	"Cohort study" means a prospective evaluation of two groups
18	of patients with only one group of patients receiving a specific
19	intervention.
20	"Commissioner" means the insurance commissioner.
21	"Complaint" means an expression of dissatisfaction, either
22	oral or written.

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	"Concurrent review" means a utilization review conducted
2	during a patient's hospital stay or course of treatment.
3	"Covered benefits" or "benefits" means those health care
4	services to which an enrollee is entitled under the terms of a
5	health benefit plan.
6	"Discharge planning" means the formal process for
7	determining, prior to discharge from a facility, the
8	coordination and management of the care that an enrollee
9	receives following discharge from a facility.
10	"Disclose" means to release, transfer, or otherwise divulge
11	protected health information to any person other than the
12	individual who is the subject of the protected health
13	information.
14	"Emergency services" means services provided to an enrollee
15	when the enrollee has symptoms of sufficient severity that a
16	layperson could reasonably expect, in the absence of medical
17	treatment, to result in placing the enrollee's health or
18	condition in serious jeopardy, serious impairment of bodily
19	functions, serious dysfunction of any bodily organ or part, or
20	death.

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 G.D. 1

1	"Enrollee" means a person who enters into a contractual
2	relationship under or who is provided with health care services
3	or benefits through a [managed care plan.] health benefit plan.
4	["Expedited appeal" means the internal review of a
5	complaint-or-an-external review of the final-internal
6	determination of an enrollee's complaint, which is completed
7	within seventy two hours after receipt of the request for
8	expedited appeal.
9	"External review" means an administrative review requested
10	by an enrollee under section 432E 6 of a managed care plan's
11	final internal determination of an enrolice's complaint.]
12	"Evidence-based standard" means the conscientious,
13	explicit, and judicious use of the current best evidence based
14	on the overall systematic review of the research in making
15	decisions about the care of individual patients.
16	"Expert opinion" means a belief or interpretation by
17	specialists with experience in a specific area about the
18	scientific evidence pertaining to a particular service,
19	intervention, or therapy.
20	"External review" means a review of an adverse
21	determination (including a final adverse determination)

1	conducted by an independent review organization pursuant to this
2	chapter.
3	"Facility" means an institution providing health care
4	services or a health care setting, including but not limited to,
5	hospitals and other licensed inpatient centers, ambulatory
6	surgical or treatment centers, skilled nursing centers,
7	residential treatment centers, diagnostic, laboratory and
8	imaging centers, and rehabilitation and other therapeutic health
9	settings.
10	"Final adverse determination" means an adverse
11	determination involving a covered benefit that has been upheld
12	by a health carrier or its designated utilization review
13	organization at the completion of the health carrier's internal
14	grievance process procedures, or an adverse determination with
15	respect to which the internal appeals process is deemed to have
16	been exhausted under section 432E-C(b).
17	"Health benefit plan" means a policy, contract, certificate
18	or agreement offered or issued by a health carrier to provide,
19	deliver, arrange for, pay or reimburse any of the costs of
20	health care services.
21	"Health care [provider"] professional" means an individual
22	licensed, accredited, or certified to provide or perform
ж	2011-2273 SB1274 CD1 SMA-3.doc

1274 S.D. 2 H.D. 3 C.D. 1

S.B. NO.

1 specified health care services in the ordinary course of 2 business or practice of a profession [-] consistent with state 3 law. "Health care provider" or "provider" means a health care 4 5 professional. 6 "Health care services" means services for the diagnosis, 7 prevention, treatment, cure, or relief of a health condition, 8 illness, injury, or disease. 9 "Health carrier" means an entity subject to the insurance 10 laws and rules of this State, or subject to the jurisdiction of 11 the commissioner, that contracts or offers to contract to provide, deliver, arrange for, pay for, or reimburse any of the 12 costs of health care services, including a sickness and accident 13 14 insurance company, a health maintenance organization, a mutual 15 benefit society, a nonprofit hospital and health service corporation, or any other entity providing a plan of health 16 insurance, health benefits or health care services. 17 "Health maintenance organization" means a health 18 19 maintenance organization as defined in section 432D-1. 20 "Independent review organization" means an independent 21 entity [that: Is-unbiased and able to make independent decisions; 22 (1)2011-2273 SB1274 CD1 SMA-3.doc

1274 S.D. 2

60

S.B. NO.

		C.D. 1	
1	- (2) -	Engages adequate numbers of practitioners with the	
2		appropriate level and type of clinical knowledge and	
3		expertise;	
4	(3)	Applies-evidence-based-decisionmaking;	
5	(4)	Demonstrates an effective process to screen external	
6		reviews for eligibility;	
7	- (5) -	Protects the enrollee's identity from unnecessary	
8		disclosure; and	
9	- (6) -	Has effective systems in place to conduct a review.]	
10	that cond	ucts independent external reviews of adverse	
11	determina	tions and final adverse determinations.	
12	"Int	ernal review" means the review under section 432E-5 of	
13	an enrolle	ee's complaint by a [managed care plan.] <u>health</u>	
14	carrier.		
15	"Mana	aged care plan" means any plan, policy, contract,	
16	certificate, or agreement, regardless of form, offered or		
17	administered by any person or entity, including but not limited		
18	to an inst	urer governed by chapter 431, a mutual benefit society	
19	governed 1	by chapter 432, a health maintenance organization	
20	governed 1	by chapter 432D, a preferred provider organization, a	
21	point of service organization, a health insurance issuer, a		
22	fiscal int	termediary, a payor, a prepaid health care plan, and	
	COMPANY AND A DESCRIPTION OF A DESCRIPTI	SB1274 CD1 SMA-3.doc	

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

61

1

S.B. NO. any other mixed model, that provides for the financing or

2 delivery of health care services or benefits to enrollees 3 through: 4 (1) Arrangements with selected providers or provider 5 networks to furnish health care services or benefits; 6 and (2)Financial incentives for enrollees to use 7 8 participating providers and procedures provided by a 9 plan; 10 provided $[\tau]$ that for the purposes of this chapter, an employee 11 benefit plan shall not be deemed a managed care plan with 12 respect to any provision of this chapter or to any requirement 13 or rule imposed or permitted by this chapter [which] that is 14 superseded or preempted by federal law. 15 "Medical director" means the person who is authorized under 16 a [managed care plan] health carrier and who makes decisions for the [plan] health carrier denying or allowing payment for 17 medical treatments, services, or supplies based on medical 18 19 necessity or other appropriate medical or health plan benefit 20 standards. "Medical necessity" means a health intervention [as 21

defined] that meets the criteria enumerated in section 432E-1.4. 22

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

61

1	"Med	lical or scientific evidence" means evidence found in
2	the follo	wing sources:
3	(1)	Peer-reviewed scientific studies published in or
4		accepted for publication by medical journals that meet
5		nationally-recognized requirements for scientific
6		manuscripts and that submit most of their published
7		articles for review by experts, who are not part of
8		the editorial staff;
9	(2)	Peer-reviewed medical literature, including literature
10		relating to therapies reviewed and approved by a
11		qualified institutional review board, biomedical
12		compendia, and other medical literature that meet the
13		criteria of the National Institutes of Health's
14		National Library of Medicine for indexing in Index
15		Medicus and Elsevier Science Ltd. for indexing in
16		Excerpta Medicas;
17	(3)	Medical journals recognized by the United States
18		Secretary of Health and Human Services under Section
19		1861(t)(2) of the federal Social Security Act;
20	(4)	The following standard reference compendia:
21		(A) The American Hospital Formulary Service-Drug
22		Information;

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

Drug Facts and Comparisons; 1 (B) The American Dental Association Accepted Dental 2 (C) Therapeutics; and 3 The United States Pharmacopeia Drug Information; 4 (D) Findings, studies, or research conducted by or under 5 (5) 6 the auspices of federal government agencies and nationally-recognized federal research institutes, 7 including: 8 The federal Agency for Healthcare Research and 9 (A) Quality; 10 (B) The National Institutes of Health; 11 (C) The National Cancer Institute; 12 (D) The National Academy of Sciences; 13 (E) The Centers for Medicare and Medicaid Services; 14 (F) The federal Food and Drug Administration; and 15 (G) Any national board recognized by the National 16 17 Institutes of Health for the purpose of evaluating the medical value of health care 18 19 services; or Any other medical or scientific evidence that is 20 (6) comparable to the sources listed in paragraphs (1) 21 through (5). 22

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	"Participating provider" means a licensed or certified
2	provider of health care services or benefits, including mental
3	health services and health care supplies, [that] who has entered
4	into an agreement with a [managed care plan] health carrier to
5	provide those services or supplies to enrollees.
6	"Prospective review" means utilization review conducted
7	prior to an admission or a course of treatment.
8	"Protected health information" means health information as
9	defined in the federal Health Insurance Portability and
10	Accountability Act and related federal rules.
11	"Randomized clinical trial" means a controlled, prospective
12	study of patients who have been randomized into an experimental
13	group and a control group at the beginning of the study with
14	only the experimental group of patients receiving a specific
15	intervention, which includes study of the groups for variables
16	and anticipated outcomes over time.
17	"Retrospective review" means a review of medical necessity
18	conducted after services that have been provided to a patient,
19	but does not include the review of a claim that is limited to an
20	evaluation of reimbursement levels, veracity of documentation,
21	accuracy of coding, or adjudication for payment.

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3

1 "Reviewer" means an independent reviewer with clinical 2 expertise either employed by or contracted by an independent 3 review organization to perform external reviews. 4 "Second opinion" means an opportunity or requirement to 5 obtain a clinical evaluation by a provider other than the one 6 originally making a recommendation for a proposed health care 7 service to assess the clinical necessity and appropriateness of 8 the initial proposed health care service. 9 "Specifically excluded" means that the coverage provisions 10 of the health care plan, when read together, clearly and 11 specifically exclude coverage for a health care service. "Utilization review" means a set of formal techniques 12 designed to monitor the use of, or evaluate the clinical 13 14 necessity, appropriateness, efficacy, or efficiency of, health care services, procedures, or settings. Techniques may include 15 ambulatory review, prospective review, second opinion, 16 certification, concurrent review, case management, discharge 17 planning, or retrospective review. 18 "Utilization review organization" means an entity that 19 conducts utilization review other than a health carrier 20 performing a review for its own health benefit plans." 21

2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

67

1 SECTION 7. Section 432E-5, Hawaii Revised Statutes, is 2 amended to read as follows: "§432E-5 Complaints and appeals procedure for enrollees. 3 4 A [managed care plan] health carrier with enrollees in this (a) 5 State shall establish and maintain a procedure to provide for 6 the resolution of an enrollee's complaints and internal appeals. 7 The procedure shall provide for expedited internal appeals under 8 section 432E-6.5. The definition of medical necessity in 9 section 432E-1.4 shall apply in a [managed care plan's] health 10 carrier's complaints and internal appeals procedures. (b) The [managed care plan] health carrier shall at all 11 12 times make available its complaints and internal appeals procedures. The complaints and internal appeals procedures 13 14 shall be reasonably understandable to the average layperson and 15 shall be provided in a language other than English upon request. A [managed care plan] health carrier shall decide any 16 (c)expedited internal appeal as soon as possible after receipt of 17 the complaint, taking into account the medical exigencies of the 18 19 case, but not later than seventy-two hours after receipt of the 20 request for expedited appeal. A [managed-care plan] health carrier shall send notice 21 (d)

22 of its final internal determination within sixty days of the

1	submission of the complaint to the enrollee, the enrollee's
2	appointed representative, if applicable, the enrollee's treating
3	provider, and the commissioner. The notice shall include the
4	following information regarding the enrollee's rights and
5	procedures:
6	(1) The enrollee's right to request an external review;
7	(2) The [sixty day] one hundred thirty day deadline for
8	requesting an external review;
9	(3) Instructions on how to request an external review; and
10	(4) Where to submit the request for an external review.
11	In addition to these general requirements, the notice shall
12	conform to the requirements of section 432E-E."
13	SECTION 8. Section 432E-6.5, Hawaii Revised Statutes, is
14	amended by amending its title to read as follows:
15	"§432E-6.5 Expedited internal appeal, when authorized;
16	standard for decision."
17	SECTION 9. Section 432E-6.5, Hawaii Revised Statutes, is
18	amended by amending subsection (a) to read as follows:
19	"(a) An enrollee may request that the [following] internal
20	appeal under section 432E-5 be conducted as an expedited
21	[appeal:
22	(1) The internal review under section 432E-5 of the
	2011-2273 SB1274 CD1 SMA-3.doc

1274 S.D. 2 H.D. 3 C.D. 1

S.B. NO.

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

-1 enrollee's complaint; or 2 (2)The external review under section 432E-6 of the 3 managed care plan's final-internal determination.] 4 appeal. If a request for expedited appeal is approved by the [managed 5 care plan or the commissioner,] health carrier, the appropriate 6 7 [review] internal appeal shall be completed within seventy-two 8 hours of receipt of the request for expedited appeal." 9 SECTION 10. Section 432E-6, Hawaii Revised Statutes, is 10 repealed. 11 ["§432E-6 External review procedure. (a) After 12 exhausting-all internal-complaint-and-appeal procedures 13 available, an enrollee, or the enrollee's treating provider or 14 appointed representative, may file a request for external review 15 of a managed care plan's final internal determination to a 16 three member review panel appointed by the commissioner composed 17 of a representative from a managed care plan not involved in the 18 complaint, a provider licensed to practice and practicing 19 medicine in Hawaii not involved in the complaint, and the 20 commissioner or the commissioner's designee in the following 21 manner:

2011-2273 SB1274 CD1 SMA-3.doc

	Page 70	S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3
		C.D. 1
1	(1)	The enrollee shall submit a request for external
2		review to the commissioner within sixty days from the
3		date of the final internal determination by the
4		managed-care-plan;
5	(2)	The-commissioner may-retain:
6		(A) Without-regard to chapter 76, an independent
7		medical expert trained in the field of medicine
8		most appropriately related to the matter under
9		review. Presentation of evidence for this
10		purpose shall be exempt from section 91 9(g); and
11		(B) The services of an independent review
12		organization from an approved list maintained by
13		the commissioner;
14	(3)	Within seven days after receipt of the request for
15		external review, a managed care plan or its designee
16		utilization review organization shall provide to the
17		commissioner or the assigned independent review
18		organization:
19		(A) Any documents or information-used in making the
20		final internal determination including the
21		enrollee's medical records;

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1		(B)	Any documentation or written information
2			submitted to the managed care plan in support of
3			the enrollee's initial complaint; and
4		(C)	A list of the names, addresses, and telephone
5	۰ ۲		numbers of each licensed health care-provider who
6			cared for the enrollee and who may have medical
7			records relevant to the external review;
8	·	prov:	ided that where an expedited appeal is involved,
9		the-r	managed care plan or its designee utilization
10		revi (ew-organization-shall-provide the documents-and
11		info	rmation-within-forty-eight-hours of receipt-of-the
12	Х (reque	est for external review.
13			Failure by the managed care plan or its designee
14		util	ization review organization to provide the
15		docur	ments and information within the prescribed time
16		perie	ods shall not delay the conduct of the external
17		revie	w Where the plan or its designee utilization
18		revie	w organization-fails-to provide-the documents and
19		info	mation within the prescribed time periods, the
20		comm	issioner may issue a decision to reverse the final
21		inter	mal-determination, in whole or part, and shall
22		prom	tly notify the independent review organization,
	0011 0073	00101	A CD1 SMA-3 doc

S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3 C.D. 1

1		the enrollee, the enrollee's appointed representative,
2		if applicable, the enrollee's treating provider, and
3		the-managed care plan of the decision;
4	(4)	Upon receipt of the request for external review and
5		upon a showing of good cause, the commissioner shall
6		appoint the members of the external review panel and
7		shall conduct a review hearing pursuant to chapter 91.
8	·	If the amount in controversy-is less than \$500, the
9		commissioner may conduct a review hearing without
10		appointing a review panel;
11	-(5)-	The review hearing shall be conducted as soon as
12		practicable, taking into consideration the medical
13		exigencies of the case; provided-that:
14		(A) The hearing shall be held no later than sixty
15		days from the date of the request for the
16		hearing; and
17		(B) An-external review conducted as an expedited
18		appeal shall be determined no later than seventy
. 19		two hours after receipt of the request for
20		external-review;
21	(6)	After considering the enrollee's complaint, the
22		managed-care-plan's-response, -and any affidavits filed

S.B. NO. ¹²⁷⁴ _{S.D. 2} _{H.D. 3} _{C.D. 1}

1		by -t	he parties, the commissioner may dismiss the
2		requ	est-for-external-review-if-it-is-determined-that
3		the-	request is frivolous or without merit; and
4	(7) -	The-	review panel shall review every final internal
5		dete	rmination to determine whether the managed care
6		plan	involved acted reasonably The review panel and
7		the-	commissioner or the commissioner's designee shall
8		eons	ider:
9		-(A)-	The terms of the agreement of the enrollee's
10			insurance policy, cvidence of coverage, or
11			similar document;
12		(B)	Whether the medical director properly applied the
13			medical necessity criteria in section 432E-1.4 in
14			making the final-internal determination;
15		-(C)	All relevant medical records;
16		-(Ð)-	The clinical standards of the plan;
17		-(E)	The information provided;
18		-(F) -	The attending physician's recommendations; and
19		-(G) -	Generally accepted practice guidelines.
20	The (:ommi,	ssioner, upon a majority vote of the panel, shall
21	issue an e	order	affirming, modifying, or reversing the decision
22	within th i	lrty-	lays of the hearing.
	A IN MALE WHEN AND A REAL PLAN AND A REAL WAVE AND TO PETER AN	en staan van de staan	74 CD1 SMA-3.doc "

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1	(b) The procedure set forth in this section shall not
2	apply to-claims or allegations of health-provider malpractice,
3.	professional negligence, or other professional fault against
4	participating providers.
5	(c) No-person shall serve on the review panel or in the
6	independent-review-organization-who,-through-a-familial
7	relationship within the second degree of consanguinity or
8	affinity, or for other reasons, has a direct and substantial
9	professional, financial, or personal interest in:
10	(1) The-plan-involved-in-the-complaint, including an
11	officer, director, or employee of the plan; or
12	(2) The treatment of the enrollee, including but not
13	limited to the developer or manufacturer of the
14	principal drug, device, procedure, or other therapy at
15	issue.
16	(d) Members of the review panel-shall be granted immunity
17	from liability and damages relating to their duties under this
18	section.
19	(e) An enrollee may be allowed, at the commissioner's
20	discretion, an award of a reasonable sum for attorney's fees and
21	reasonable costs incurred in connection with the external review
22	under-this section, unless the commissioner in an administrative
	2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

75

1	proceeding-determines-that the appeal was unreasonable,
2	fraudulent, excessive, or frivolous.
3	(f) Disclosure of an enrollee's protected health
4	information shall be limited to disclosure for purposes relating
5	to the external review."]
6	SECTION 11. The insurance commissioner shall submit a
7	report to the legislature no later than twenty days prior to the
8	convening of the 2012 regular session on the implementation of
9	this Act including the names of all independent review
10	organizations contracted by the State pursuant to section
11	432E-L, Hawaii Revised Statutes, and data on the number of
12	requests for external review and outcomes of external reviews as
13	maintained by each independent review organization pursuant to
14	section 432E-K(b), Hawaii Revised Statutes.

15 SECTION 12. The insurance commissioner shall assist the 16 department of human services and the Hawaii employer-union health benefits trust fund in compiling data relating to each 17 entity's own administrative review process comparable to that 18 19 maintained by independent review organizations pursuant to 20 section 432E-K(b), Hawaii Revised Statutes, and submitting a 21 report of the data and findings to the legislature no later than 22 twenty days prior to the convening of the 2012 regular session.

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

1 The report submitted pursuant to this section shall include a 2 comparison between outcomes in the review processes maintained by the department of human services and Hawaii employer-union 3 health benefits trust fund, respectively, and outcomes of the 4 5 review processes of independent review organizations, as well as 6 an analysis of whether or not consumers would have achieved 7 better access to health care services under a review process 8 maintained by an independent review organization.

9 SECTION 13. If any provision of this Act, or the 10 application thereof to any person or circumstance is held 11 invalid, the invalidity does not affect other provisions or 12 applications of the Act, which can be given effect without the 13 invalid provision or application, and to this end the provisions 14 of this Act are severable.

15 SECTION 14. This Act shall be construed at all times in 16 conformity with the federal Patient Protection and Affordable 17 Care Act, Public Law No. 111-148. If any provision of this part 18 is interpreted to violate the Patient Protection and Affordable 19 Care Act, the commissioner is authorized to adopt by emergency 20 rule-making procedures, any rules as necessary to conform the 21 provisions and procedures of this part with the Patient

22 Protection and Affordable Care Act.

S.B. NO. ¹²⁷⁴ s.d. 2 H.D. 3 C.D. 1

SECTION 15. In codifying the new sections added by section
 2 of this Act, the revisor of statutes shall substitute
 appropriate section numbers for the letters used in designating
 the new sections in this Act.

5 SECTION 16. Statutory material to be repealed is bracketed6 and stricken. New statutory material is underscored.

7 SECTION 17. This Act shall take effect on June 30, 2011; 8 provided that if the United States Department of Health and 9 Human Services by rule or other written quidance extends the 10 time period for the State's existing external review process 11 under section 432E-6, Hawaii Revised Statutes, to any later date 12 during 2011, then the effective date of this Act shall be the 13 sooner of the end date of the transition period or January 1, 2012; provided further that if the external review requirements -14 15 of the federal Patient Protection and Affordable Care Act of 2010 are held unconstitutional by the United States Supreme 16 17 Court, this Act shall be repealed as of the date that the United States Supreme Court issues its opinion and chapter 432E, Hawaii 18 19 Revised Statutes, shall be reenacted in the form in which it 20 existed as of the day before the United States Supreme Court 21 issued its decision.

S.B. NO. ¹²⁷⁴ S.D. 2 H.D. 3 C.D. 1

APPROVED this 1 2 day of JUL , 2011

Mail aberrombre

GOVERNOR OF THE STATE OF HAWAII